Plain-English translation of NCT05206890 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →This study is tracking how fluzoparib, a newer type of ovarian cancer medication called a PARP inhibitor, works when used to treat ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in real-world medical settings. Researchers will collect information from your medical records as you receive this treatment to understand how well it helps patients and whether it is safe. The goal is to learn more about how this medication performs outside of controlled research studies.
Most women with ovarian cancer experience their cancer returning within a few years, even after initial successful treatment. This medication has shown promise in clinical trials at slowing cancer recurrence, but researchers need to gather more information about how it works for patients in everyday medical practice to better understand its benefits and risks.
You likely qualify if…
You likely don't qualify if…
You would continue to receive your cancer treatment, including the medication fluzoparib, as planned with your regular doctor. The study involves sharing your medical records and information about how you respond to treatment over time—you are not being asked to do anything different than your standard care. Researchers will track your progress and outcomes to build a better understanding of how this treatment works for patients like you.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China